| ［1］ |
中华医学会皮肤性病学分会银屑病专业委员会. 中国银屑病诊疗指南（2023版）［J］. 中华皮肤科杂志, 2023,56（7）:573⁃625. DOI: 10.35541/cjd.20220839.
|
| ［2］ |
Diotallevi F, Campanati A, Martina E, et al. The role of nutrition in immune⁃mediated, inflammatory skin disease: a narrative review［J］. Nutrients, 2022,14（3）:591. DOI: 10.3390/nu14030591.
|
| ［3］ |
Visser MJE, Kell DB, Pretorius E. Bacterial dysbiosis and translocation in psoriasis vulgaris［J］. Front Cell Infect Microbiol, 2019,9:7. DOI: 10.3389/fcimb.2019.00007.
|
| ［4］ |
Polkowska⁃Pruszynska B, Gerkowicz A, Krasowska D. The gut microbiome alterations in allergic and inflammatory skin diseases ⁃ an update［J］. J Eur Acad Dermatol Venereol, 2020,34（3）:455⁃464. DOI: 10.1111/jdv.15951.
|
| ［5］ |
Groeger D, O'Mahony L, Murphy EF, et al. Bifidobacterium infantis 35624 modulates host inflammatory processes beyond the gut［J］. Gut Microbes, 2013,4（4）:325⁃339. DOI: 10.4161/gmic.25487.
|
| ［6］ |
殷广, 李剑锋, 孙玉发, 等. 肠微生态移植重建治疗重度银屑病的临床研究［J］. 中华内科杂志, 2019,58（10）:782⁃785. DOI: 10.3760/cma.j.issn.0578⁃1426.2019.10.011.
|
| ［7］ |
Kragsnaes MS, Kjeldsen J, Horn HC, et al. Safety and efficacy of faecal microbiota transplantation for active peripheral psoriatic arthritis: an exploratory randomised placebo⁃controlled trial［J］. Ann Rheum Dis, 2021,80（9）:1158⁃1167. DOI: 10.1136/annrheumdis⁃2020⁃219511.
|
| ［8］ |
Chen YN, Chi CC. Levels of evidence and study designs: a brief introduction to dermato⁃epidemiologic research methodology［J］. Dermatologica Sinica, 2023,41（4）:199⁃205. DOI: 10.4103/ds.DS⁃D⁃23⁃00159.
|
| ［9］ |
中华人民共和国国家卫生健康委员会医政司. 原发性肝癌诊疗指南（2024年版）［J］. 中华消化外科杂志, 2024,23（4）:429⁃478. DOI: 10.3760/cma.j.cn115610⁃20240415⁃00203.
|
| ［10］ |
Scher JU, Ubeda C, Artacho A, et al. Decreased bacterial diversity characterizes the altered gut microbiota in patients with psoriatic arthritis, resembling dysbiosis in inflammatory bowel disease［J］. Arthritis Rheumatol, 2015,67（1）:128⁃139. DOI: 10.1002/art.38892.
|
| ［11］ |
王丽玮, 徐浩翔, 段志敏, 等. 基于 16S rRNA 基因测序的寻常型银屑病患者肠道菌群差异研究［J］. 中华皮肤科杂志, 2020,53（9）:692⁃697. DOI: 10.35541/cjd.20200208.
|
| ［12］ |
Doaa M, Dalia M, Ahmed FS. Gut bacterial microbiota in psoriasis: a case control study［J］. Afr J Microbiol Res, 2016,10（33）:1337⁃1343. DOI: 10.5897/AJMR2016.8046.
|
| ［13］ |
Hidalgo⁃Cantabrana C, Gomez J, Delgado S, et al. Gut microbiota dysbiosis in a cohort of patients with psoriasis［J］. Br J Dermatol, 2019,181（6）:1287⁃1295. DOI: 10.1111/bjd.17931.
|
| ［14］ |
Zhang X, Shi L, Sun T, et al. Dysbiosis of gut microbiota and its correlation with dysregulation of cytokines in psoriasis patients［J］. BMC Microbiol, 2021,21（1）:78. DOI: 10.1186/s12866⁃021⁃02125⁃1.
|
| ［15］ |
Codoner FM, Ramirez⁃Bosca A, Climent E, et al. Gut microbial composition in patients with psoriasis［J］. Sci Rep, 2018,8（1）:3812. DOI: 10.1038/s41598⁃018⁃22125⁃y.
|
| ［16］ |
Tan L, Zhao S, Zhu W, et al. The Akkermansia muciniphila is a gut microbiota signature in psoriasis［J］. Exp Dermatol, 2018,27（2）:144⁃149. DOI: 10.1111/exd.13463.
|
| ［17］ |
Ashrafian F, Behrouzi A, Shahriary A, et al. Comparative study of effect of Akkermansia muciniphila and its extracellular vesicles on Toll⁃like receptors and tight junction［J］. Gastroenterol Hepatol Bed Bench, 2019,12（2）:163⁃168. DOI: 10.22037/GHFBB.V12I2. 1537.
|
| ［18］ |
Hiippala K, Jouhten H, Ronkainen A, et al. The potential of gut commensals in reinforcing intestinal barrier function and alleviating inflammation［J］. Nutrients, 2018,10（8）:988. DOI: 10.3390/nu10080988.
|
| ［19］ |
Eppinga H, Sperna Weiland CJ, Thio HB, et al. Similar depletion of protective Faecalibacterium prausnitzii in psoriasis and inflammatory bowel disease, but not in hidradenitis suppurativa［J］. J Crohns Colitis, 2016,10（9）:1067⁃1075. DOI: 10.1093/ecco⁃jcc/jjw070.
|
| ［20］ |
De Francesco MA, Caruso A. The gut microbiome in psoriasis and Crohn's disease: is its perturbation a common denominator for their pathogenesis?［J］. Vaccines（Basel）, 2022,10（2）:244. DOI: 10.3390/vaccines10020244.
|
| ［21］ |
Sikora M, Stec A, Chrabaszcz M, et al. Gut microbiome in psoriasis: an updated review［J］. Pathogens, 2020,9（6）:463. DOI: 10.3390/pathogens9060463.
|
| ［22］ |
Zhao Q, Yu J, Zhou H, et al. Intestinal dysbiosis exacerbates the pathogenesis of psoriasis⁃like phenotype through changes in fatty acid metabolism［J］. Signal Transduct Target Ther, 2023,8（1）:40. DOI: 10.1038/s41392⁃022⁃01219⁃0.
|
| ［23］ |
De Jesus⁃Gil C, Ruiz⁃Romeu E, Ferran M, et al. CLA+ T cell response to microbes in psoriasis［J］. Front Immunol, 2018,9:1488. DOI: 10.3389/fimmu.2018.01488.
|
| ［24］ |
Zakostelska Z, Malkova J, Klimesova K, et al. Intestinal microbiota promotes psoriasis⁃like skin inflammation by enhancing Th17 response［J/OL］. PLoS One, 2016,11（7）:e0159539［2025⁃09⁃25］. https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0159539. DOI: 10.1371/journal.pone. 0159539.
|
| ［25］ |
Pantelyushin S, Haak S, Ingold B, et al. Rorgammat+ innate lymphocytes and gammadelta T cells initiate psoriasiform plaque formation in mice［J］. J Clin Invest, 2012,122（6）:2252⁃2256. DOI: 10.1172/JCI61862.
|
| ［26］ |
Okada K, Matsushima Y, Mizutani K, et al. The role of gut microbiome in psoriasis: oral administration of Staphylococcus aureus and Streptococcus danieliae exacerbates skin inflammation of imiquimod⁃induced psoriasis⁃like dermatitis［J］. Int J Mol Sci, 2020,21（9）:3303. DOI: 10.3390/ijms21093303.
|
| ［27］ |
Gopalarathinam R, Sankar R, Zhao SS. Role of anti⁃inflammatory diet and fecal microbiota transplant in psoriatic arthritis［J］. Clin Ther, 2024,46（7）:588⁃596. DOI: 10.1016/j.clinthera.2024.05.005.
|
| ［28］ |
Chen HL, Zeng YB, Zhang ZY, et al. Gut and cutaneous microbiome featuring abundance of Lactobacillus reuteri protected against psoriasis⁃like inflammation in mice［J］. J Inflamm Res, 2021,14:6175⁃6190. DOI: 10.2147/JIR.S337031.
|
| ［29］ |
Zou X, Zou X, Gao L, et al. Gut microbiota and psoriasis: pathogenesis, targeted therapy, and future directions［J］. Front Cell Infect Microbiol, 2024,14:1430586. DOI: 10.3389/fcimb. 2024.1430586.
|
| ［30］ |
Kragsnaes MS, Jensen JRB, Nilsson AC, et al. Dynamics of inflammation⁃associated plasma proteins following faecal microbiota transplantation in patients with psoriatic arthritis and healthy controls: exploratory findings from the FLORA trial［J］. RMD Open, 2024,10（1）:e003750. DOI: 10.1136/rmdopen⁃2023⁃003750.
|
| ［31］ |
中国微生态调节剂临床应用专家共识（2025版）编写组. 中国微生态调节剂临床应用专家共识（2025版）［J］. 中国微生态学杂志, 2025,37（8）:869⁃887. DOI: 10.13381/j.cnki.cjm.2025 08001.
|
| ［32］ |
中华医学会肠外肠内营养学分会，上海预防医学会微生态专业委员会. 肠道菌群移植供体筛选与管理中国专家共识（2022版）［J］. 中华胃肠外科杂志, 2022,25（9）:757⁃765. DOI: 10.3760/cma.j.cn441530⁃20220606⁃00246.
|
| ［33］ |
Cammarota G, Ianiro G, Tilg H, et al. European consensus conference on faecal microbiota transplantation in clinical practice［J］. Gut, 2017,66（4）:569⁃580. DOI: 10.1136/gutjnl⁃2016⁃313017.
|
| ［34］ |
Kassam Z, Dubois N, Ramakrishna B, et al. Donor screening for fecal microbiota transplantation［J］. N Engl J Med, 2019,381（21）:2070⁃2072. DOI: 10.1056/NEJMc1913670.
|
| ［35］ |
Cammarota G, Ianiro G, Kelly CR, et al. International consensus conference on stool banking for faecal microbiota transplantation in clinical practice［J］. Gut, 2019,68（12）:2111⁃2121. DOI: 10.1136/gutjnl⁃2019⁃319548.
|
| ［36］ |
何植, 张发明. 中华粪菌库的原则、方案和风险管理 ［J］. 胃肠病学, 2017,22（4）:193⁃198. DOI: 10.3969/j.issn.1008⁃7125. 2017.04.001.
|
| ［37］ |
中华医学会肠外肠内营养学分会, 中国国际医疗保健促进交流会加速康复外科分会, 中国微生态治疗创新联盟, 等. 菌群移植标准化方法学的建立与临床应用中国专家共识［J］. 中华胃肠外科杂志, 2020,23（S1）:5⁃13. DOI: 10.3760/cma.j.cn44 1530⁃20200420⁃00231.
|
| ［38］ |
中国抗癌协会肿瘤与微生态专业委员会, 中国感染免疫与微生态研究转化协作组. 肠菌移植制备和质控实验室标准化技术规范中国专家共识（2023版）［J］. 中国微生态学杂志, 2024,36（6）:705⁃711+717. DOI: 10.13381/j.cnki.cjm.202406013.
|
| ［39］ |
国家卫生健康委员会医院管理研究所, 中华医学会肠外肠内营养学分会, 中华医学会肠外肠内营养学分会肠道微生态协作组. 肠道菌群移植临床应用管理中国专家共识（2022版）［J］. 中华胃肠外科杂志, 2022,25（9）:747⁃756. DOI: 10.3760/cma.j.cn441530⁃20220725⁃00324.
|
| ［40］ |
Nivet C, Duhalde V, Beaurain M, et al. Fecal microbiota transplantation for refractory Clostridioides difficile infection is effective and well tolerated even in very old subjects: a real⁃life study［J］. J Nutr Health Aging, 2022,26（3）:290⁃296. DOI: 10. 1007/s12603⁃022⁃1756⁃1.
|
| ［41］ |
Ding X, Yang X, Wang H. Methodology, efficacy and safety of fecal microbiota transplantation in treating inflammatory bowel disease［J］. Medicine in Microecology, 2020,6:100028. DOI: 10. 1016/j.medmic.2020.100028.
|
| ［42］ |
Goldenberg SD, Batra R, Beales I, et al. Comparison of different strategies for providing fecal microbiota transplantation to treat patients with recurrent Clostridium difficile infection in two English hospitals: a review［J］. Infect Dis Ther, 2018,7（1）:71⁃86. DOI: 10.1007/s40121⁃018⁃0189⁃y.
|
| ［43］ |
Youngster I, Mahabamunuge J, Systrom HK, et al. Oral, frozen fecal microbiota transplant（FMT） capsules for recurrent Clostridium difficile infection［J］. BMC Med, 2016,14（1）:134. DOI: 10.1186/s12916⁃016⁃0680⁃9.
|
| ［44］ |
Wang JW, Kuo CH, Kuo FC, et al. Fecal microbiota transplantation: review and update［J］. J Formos Med Assoc, 2019,118（Suppl 1）:S23⁃S31. DOI: 10.1016/j.jfma.2018.08.011.
|
| ［45］ |
向丽园, 张发明. 粪菌移植在艰难梭菌感染治疗中的应用［J］. 临床荟萃, 2018,33（5）:385⁃389. DOI: 10.3969/j.issn.1004⁃583X.2018.05.005.
|
| ［46］ |
Minkoff NZ, Aslam S, Medina M, et al. Fecal microbiota transplantation for the treatment of recurrent Clostridioides difficile （Clostridium difficile）［J］. Cochrane Database Syst Rev, 2023,4（4）:CD013871. DOI: 10.1002/14651858.CD013871.pub2.
|
| ［47］ |
Huang C, Yi P, Zhu M, et al. Safety and efficacy of fecal microbiota transplantation for treatment of systemic lupus erythematosus: an EXPLORER trial［J］. J Autoimmun, 2022,130:102844. DOI: 10.1016/j.jaut.2022.102844.
|
| ［48］ |
中华医学会肠外肠内营养学分会, 中国国际医疗保健促进交流会加速康复外科分会, 中国微生态治疗创新联盟, 等. 菌群移植途径的选择与建立临床应用中国专家共识［J］. 中华胃肠外科杂志, 2020,23（S1）:14⁃20. DOI: 10.3760/cma.j.cn441530⁃ 20200420⁃00228.
|
| ［49］ |
Xin Y, Huang C, Zheng M, et al. Fecal microbiota transplantation in the treatment of systemic lupus erythematosus: what we learnt from the explorative clinical trial［J］. J Autoimmun, 2023,141:103058. DOI: 10.1016/j.jaut.2023.103058.
|
| ［50］ |
DeLeon O, Mocanu M, Tan A, et al. Microbiome mismatches from microbiota transplants lead to persistent off⁃target metabolic and immunomodulatory effects［J］. Cell, 2025,188（15）:3927⁃3941. DOI: 10.1016/j.cell.2025.05.014.
|
| ［51］ |
Navarro⁃López V, Martínez⁃Andrés A, Ramírez⁃Boscá A, et al. Efficacy and safety of oral administration of a mixture of probiotic strains in patients with psoriasis: a randomized controlled clinical trial［J］. Acta Derm Venereol, 2019,99（12）:1078⁃1084. DOI: 10.2340/00015555⁃3305.
|
| ［52］ |
Buhaș MC, Candrea R, Gavrilaș LI, et al. Transforming psoriasis care: probiotics and prebiotics as novel therapeutic approaches［J］. Int J Mol Sci, 2023,24（13）:11225. DOI: 10.3390/ijms2413 11225.
|
| ［53］ |
Hills RD Jr, Pontefract BA, Mishcon HR, et al. Gut microbiome: profound implications for diet and disease［J］. Nutrients, 2019,11（7）:1613. DOI: 10.3390/nu11071613.
|
| ［54］ |
Fishbein SRS, Mahmud B, Dantas G. Antibiotic perturbations to the gut microbiome［J］. Nat Rev Microbiol, 2023,21（12）:772⁃788. DOI: 10.1038/s41579⁃023⁃00933⁃y.
|
